compound diclofenac sodium

Phase 2Small molecule

TThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

compound diclofenac sodium is one of 3 small molecule programs targeting Acupuncture. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AcupunctureNot yet recruiting

AcupuncturePhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Acupuncture

#DrugCompanyPhaseTrials

compound diclofenac sodium

TThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Phase 2

1 2

Artificial Tears

UUniversity Hospital of Patras

Preclinical

1 3

Lidocaine /ml

UUniversity Health Network, Toronto

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Not yet recruiting

Acupuncture

NCT06982755

Clinical

Trials by Indication[1]

Acupuncture1 trial

Acupuncture Versus Compound Diclofenac Sodium for Pain Relief in Non-Traumatic Acute Abdominal

Not yet recruiting·TThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine·Phase 1/2·NCT06982755·176 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for compound diclofenac sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — compound diclofenac sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for compound diclofenac sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

compound diclofenac sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acupuncture1 trial

References

Drug Info

Quick Facts

Related News